DEF: OmniAb, Inc. Announces 2025 Annual Meeting of Shareholders

OmniAb, Inc. has scheduled its 2025 Annual Meeting of Shareholders for June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• OmniAb, Inc. will hold its 2025 Annual Meeting of Shareholders on June 17, 2025, at 8:00 a.m. Pacific Time at the company's headquarters in Emeryville, CA.
• Shareholders of record as of April 23, 2025, are entitled to vote on the election of two Class III directors, Carolyn R. Bertozzi, Ph.D. and John Higgins, each for a three-year term expiring in 2028.
• Shareholders will also vote to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board of directors recommends voting 'FOR' the election of the director nominees and 'FOR' the ratification of Ernst & Young LLP.
• Proxy materials are primarily available online, with a Notice of Internet Availability sent to most shareholders.
• Shareholders can vote via the internet, telephone, or by mail using the provided proxy card.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions, reflecting a professional and compliant approach to corporate governance.

Positives

• The company is committed to good corporate governance practices.
• The board of directors is composed of a majority of independent directors.
• The company has a compensation clawback policy.
• The company conducts annual self-evaluations of the board and committees.
• The company has stock ownership guidelines for directors.
• The company is environmentally conscious and seeks to operate its business in a sustainable manner.
• The company has established employee-sponsored committees to further drive our corporate responsibility initiatives.

Risks

• The document mentions the risk oversight process includes receiving regular reports from board committees and members of senior management to enable our board of directors to understand the Company’s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk.

Future Outlook

The company aims to enhance the probability of success, reduce costs, and accelerate development timelines for its partners through its antibody discovery solutions.

Management Comments

• Matthew W. Foehr, President and CEO, cordially invites shareholders to attend the Annual Meeting and urges them to vote their shares.
• Charles S. Berkman, Chief Legal Officer and Secretary, states that the board is committed to the highest legal and ethical standards.

Industry Context

OmniAb operates in the competitive biopharmaceutical industry, licensing its antibody discovery technology to pharmaceutical and biotech companies and academic institutions.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• However, it mentions that the HCMCC uses a peer group of companies to assess the company's compensation programs.
• The document mentions that the company aims to enhance the probability of success, reduce costs, and accelerate development timelines for its partners through its antibody discovery solutions.

Related Party Transactions

• On November 13, 2024, we entered into a Commercial Platform License and Services Agreement (the License) with Photinia Biosciences, Inc. (Photinia), pursuant to which we granted a license to use certain technology and provide certain services to Photinia relating to the generation of antibodies.
• Jennifer Cochran, Ph.D., a member of our board of directors, is a co-founder of, and a stockholder in, Photinia.
• In addition, Dr. Cochran beneficially owns equity interests in, and is a co-founder and Chief Scientific Advisor of, Red Tree Venture Capital, an investment fund that beneficially owned a majority of the equity interests in Photinia at the time of the License.

Stakeholder Impact

• Shareholders are asked to vote on key governance matters.
• Employees are impacted by the company's compensation and benefits policies.
• The company's partners benefit from its antibody discovery solutions.
• The healthcare community benefits from the company's mission to enable the rapid development of innovative therapeutics.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 17, 2025.
• The company will file the final voting results with the SEC.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Shareholders, Election of Directors, Ernst & Young, Corporate Governance, OmniAb